The US Food and Drug Administration on Monday approved a low-cost version of a twice-yearly HIV prevention shot, bringing the breakthrough drug closer to market in low-income countries.
The approval was announced by Dr Reddy's Laboratories, the Indian maker of the generic version of lenacapavir, and by Unitaid, a global health initiative.
The generic will be available for $40 per person per year in 120 countries, under a pricing agreement announced in September 2025 between Dr Reddy's and Unitaid, the African health research institute Wits RHI, and the Clinton Health Access Initiative (CHAI).
"This is a moment of immense pride for all of us at Dr Reddy's," said Deepak Sapra, CEO of Pharmaceutical Services and API at Dr Reddy's, in a statement.
"Developing and manufacturing a complex long-acting injectable like lenacapavir at an affordable price required strong scientific capabilities and manufacturing expertise to address an urgent access need."
"Unitaid's early risk-taking is helping shorten the time between a scientific breakthrough and real access in countries," added Philippe Duneton, Unitaid's executive director.
Lenacapavir was first developed by US pharmaceutical company Gilead and approved in June 2025 after proving more than 99.9 per cent effective in large clinical trials.
A twice-yearly injectable that is akin to a vaccine - albeit without training the immune system - can be a more effective way to administer HIV pre-exposure prophylaxis (PrEP) than daily pills, which first won US approval in 2012 but only work if taken consistently.
Read the original article on Daily Trust.
AllAfrica publishes around 600 reports a day from more than 90 news organizations and over 500 other institutions and individuals, representing a diversity of positions on every topic. We publish news and views ranging from vigorous opponents of governments to government publications and spokespersons. Publishers named above each report are responsible for their own content, which AllAfrica does not have the legal right to edit or correct.
Articles and commentaries that identify allAfrica.com as the publisher are produced or commissioned by AllAfrica. To address comments or complaints, please Contact us.
AllAfrica is a voice of, by and about Africa - aggregating, producing and distributing 600 news and information items daily from over 90 African news organizations and our own reporters to an African and global public. We operate from Cape Town, Dakar, Abuja, Johannesburg, Nairobi and Washington DC.
To complete the process, please follow the instructions in the email we just sent you.
There was a problem processing your submission. Please try again later.